This study demonstrated that FOXC1 activates certain anti-metastatic genes in the Luminal B breast cancer subset and that any pro-tumor effects of FOXC1 are overridden by the anti-metastatic functions of FOXC1 leading to an overall pro-survival effect in Luminal B patients expressing higher FOXC1 levels. The gene discussed is FOXC1; the disease is breast carcinoma.